Skip to main content
. 2022 Jun 9:10.2217/fon-2022-0148. doi: 10.2217/fon-2022-0148

Figure 2. Anti-SARS-CoV-2 S1 IgG antibody levels in previously infected and non-previously infected cancer patients.

Figure 2.

(A) Differences in antibody titers against S1 protein of SARS-CoV-2 in cancer patients at different time points in patients without previous COVID-19 infection (blue) and those with prior COVID-19 infection (red); Wilcoxon signed-rank test. (B) Proportion of cancer patients with antibodies against S1 protein of SARS-CoV-2 at different time points in patients without previous COVID-19 infection (blue borders) and in patients with prior COVID-19 infection (red borders); chi-square test. Patients with IgG values ≥880 ng/ml (≥44 BAU/ml) were considered to have a high probability of immune protection against SARS-CoV-2.